CPHI Webinar Series
Co-processing: A Multifaceted Approach for Enhancing Density & Powder Flow
What will this webinar address?
Discover the Power of Co-processing: Unleashing the Potential of Pharmaceutical Manufacturing. Our multifaceted co-processing technology is a game-changer, boosting density, optimizing powder flow, ensuring content uniformity, and enhancing solubility-dissolution. But that's not all – it also goes above and beyond, safeguarding your workforce from potent Active Pharmaceutical Ingredients (APIs). Embrace innovation and efficiency with our cutting-edge co-processing solutions and elevate your pharmaceutical production to new heights. Experience the future of manufacturing!
- Understand the potential of co-processing technology - what are the key benefits over existing solutions?
- Discover how the industry is embracing co-processing technology
- Learn some of the common techniques on the co-processing technology platform
- See examples of how co-processing can improve powder flow and density, and improve formulation rigidity
San Kiang is the Chief Technology Officer Drug Product at J-Star Research/Porton. He deploys particle engineering and co-processing techniques to resolve API and formulation issues especially those related to powder flow and dosage form dissolution rates.
As a Research Professor at Rutgers University, he worked on research projects in the Engineering Research Center for Structured Organic Particles and the Chemical Engineering Department. Research focus is on continuous manufacturing (CM) and particle engineering, more specifically how the material properties of API can be engineered and how these properties affect CM equipment train and drug product performance.
San Kiang has 35 years of pharmaceutical development and technology transfer experience in Bristol-Myers Squibb covering both Active Pharmaceutical Ingredient (API) and Drug Product (DP) areas. PhD chemical engineer with experience in directing multi-disciplinary teams in pharmaceutical, chemical, and biochemical development and manufacture. He directed and/or participated in 12 NDA projects that were eventually commercialized and successfully participated in one of the first NDA filings using QBD paradigm. In this filing, he led the use of risk assessment and process modeling with emphasis on fundamental mechanistic understanding for drug development. Well recognized expert in crystallization, particle engineering, reaction engineering, continuous processing (both DP and API), as well as the design of pharmaceutical composite materials through co-processing.
Kaushalendra leads advancements in particle engineering and drug product risk assessment. He skillfully employs techniques like particle engineering, crystal engineering, and coprocessing to optimize the behavior and effectiveness of active pharmaceutical ingredients (API) and their respective formulations, placing an emphasis on enhancing powder flow, density, solubility, and dissolution rates.
This webinar is brought to you by
19th September, 2023
4pm CET / 10am EST
Get the latest from CPHI in your inbox every week.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance